Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsUpgradesPrice Target
Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.
Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.